All In MedTech

FDA Clearance Tracker · N970003

PULSAR/PULSAR MAX IMPLANTABLE PULSE GENERATOR SYSTEM WITH CONSULT SOFTWARE

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jun 3, 1999 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 3, 1999

Approved

Time to decision

633 days

Received Sep 8, 1997. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
N970003
Device name
PULSAR/PULSAR MAX IMPLANTABLE PULSE GENERATOR SYSTEM WITH CONSULT SOFTWARE
Applicant location
St Paul, MN
Received
Sep 8, 1997
Decided
Jun 3, 1999
Decision
Approved
Supplements
160 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LWP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR YOUR PRODUCT DEVELOPMENT PROTOCOL (PDP) FOR THE:GUIDANT PULSAR MODELS 470, 970, 972, 1172, 1272 PULSE GENERATORS, GUIDANT PULSAR MAX MODELS 1170, 1171, 1270 PULSE GENERATORS, AND GUIDANT CONSULT (MODEL 2890) SOFTWARE.GUIDANT PULSAR/PULSAR MAX SERIES PACEMAKERS ARE INDICATED FOR THE FOLLOWING: SYMPTOMATIC PAROXYSMAL OR PERMANENT SECOND. OR THIRD-DEGREE AV BLOCK SYMPTOMATIC BILATERAL BUNDLE BRANCH BLOCKSYMPTOMATIC PAROXYSMAL OR TRANSIENT SINUS NODE DYSFUNCTIONS WITH OR WITHOUT ASSOCIATED AV CONDUCTION DISORDERS (EG, SINUS BRADYCARDIA, SINUS ARREST, SINOATRIAL [SA] BLOCK) BRADYCARDIA-TACHYCARDIA SYNDROME TO PREVENT SYMPTOMATIC BRADYCARDIA OR SOME FORMS OF SYMPTOMATIC TACHYARRHYTHMIAS NEUROVASCULAR (VASOVAGAL) SYNDROMES OR HYPERSENSITIVE CAROTID SINUS SYNDROMES ADAPTIVE-RATE PACING IS INDICATED FOR PATIENTS WHO MAY BENEFIT FROM INCREASED PACING RATES CONCURRENT WITH INCREASES IN MINUTE VENTILATION AND/OR LEVEL OF PHYSICAL ACTIVITY. THE PULSAR¿/PULSAR MAX¿ SERIES PACEMAKERS' DUAL CHAMBER AND ATRIAL TRACKING MODES ARE ALSO INDICATED FOR PATIENTS WHO MAY BENEFIT FROM MAINTENANCE OF AV SYNCHRONY. DUAL CHAMBER MODES ARE SPECIFICALLY INDICATED FOR TREATMENT OF THE FOLLOWING:CONDUCTION DISORDERS THAT REQUIRE RESTORATION OF AV SYNCHRONY, INCLUDING VARYING DEGREES OF AV BLOCK VVI INTOLERANCE (E.G., PACEMAKER SYNDROME) IN THE PRESENCE OF PERSISTENT SINUS RHYTHM LOW CARDIAC OUTPUT OR CONGESTIVE HEART FAILURE SECONDARY TO BRADYCARDIA.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LWP. The earliest in FDA's data is P780009, decided Mar 27, 1979.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.